Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study
Launched by LEO PHARMA · Dec 17, 2015
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Psoriasis vulgaris on body
- • Patients planned to receive topical treatment on the body with calcipotriol/betamethasone gel
- • Written informed consent
- Exclusion Criteria:
- • No or very mild symptoms of psoriasis vulgaris on the body at study start
- • Any on-going treatments at study start with topical steroids, salicylic acid or its combination
- • Other topical treatment for body psoriasis
- • Pregnancy or planned pregnancy within treatment period
- • Contraindications according to prescribing information.
About Leo Pharma
LEO Pharma is a global pharmaceutical company dedicated to developing innovative therapies for dermatological and critical care conditions. With a strong focus on research and development, LEO Pharma aims to improve the lives of patients through advanced treatments and a commitment to high-quality standards. The company collaborates with healthcare professionals and stakeholders to address unmet medical needs and drive scientific progress in the field. Through its clinical trials, LEO Pharma seeks to enhance therapeutic options and provide effective solutions for patients suffering from skin diseases and other related health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saratov, , Russian Federation
Patients applied
Trial Officials
Dmitry Petrunin, MD, PhD
Study Director
LEO Pharmaceutical Products LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials